Join us at the Influenza Vaccines for the World Conference in Lausanne, Switzerland, April 19-21, 2017. Dr. Kathy Rowlen will be speaking about the VaxArray platform and I&L Biosystems will be representing InDevR with a table top booth. Please contact us if you wish to schedule a time to meet.
Update on July 7, 2015: The presentations given at EDUFLUVAC can be viewed here.
InDevR Presents its Latest Advance for Immunoassay Standardization at EDUFULVAC Workshop
Cypher One System Fully Automates and Standardizes Analysis of Hemagglutination and Hemagglutination Inhibition Assays
Boulder, CO – June 17, 2015 – InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, today announced the company will present tomorrow at the EDUFLUVAC Consortium workshop on standardization for immunoassays, which is being held as part of the organization’s mission to develop a universal influenza vaccine.
The workshop will bring together experts from research institutions, industry, public health and regulatory agencies with the aim of evaluating the most promising assays for the assessment of future influenza vaccines, and to explore a path towards the standardization of such assays.
Dr. Kathy Rowlen, Chief Executive Officer of InDevR, Inc., will present an overview of the company’s new Cypher One™ system, which could be used to standardize the hemagglutination inhibition assays that are used to determine new strains of influenza. Currently, hemagglutination assays rely on subjective, manual interpretation, which can lead to significant variations in the measurement between technicians and laboratories. The Cypher One system provides automated imaging and standardized interpretation of these assays in less than one minute.
Dr. Rowlen commented: “A number of industrial and government groups, including the EDUFLUVAC Consortium, are calling for improved standardization in vaccine characterization. In response to these initiatives, InDevR has developed an optical analyzer with proprietary software to automate and standardize results interpretation, thereby improving vaccine characterization. We are delighted to share our exciting advance with the community and to participate in this important event.”
The workshop, which takes place at the U.K. National Institute for Biological Controls and Standards (NIBSC) on June 18 – 19, 2015, is being co-organized and co-sponsored by the U.S. National Institute of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID).
InDevR has a demonstrated commitment to innovative solutions for the life science industry. With focus on enhancing vaccines and other biotherapeutics, InDevR has emerged as a leader in progressive new analytical technologies that enable accelerated development and manufacturing of these life-saving products. For more information about the company and products, please visit www.indevr.com or call 303-402-9100.
HHS is not responsible for the contents of this release. The statements contained in this release do not constitute endorsement or recommendation by the U.S. Government or HHS.
Sales & Marketing Manager
Bioscribe, Inc. – Media Relations for InDevR